Hepatitis B Virus

New data from V.P. Papadopoulos et al illuminate research in hepatitis B virus

Published in Hepatitis Weekly, May 4th, 2009

"The efficacy of pegylated interferon alfa-2b alone or in combination with lamivudine for the treatment of patients with hepatitis B e antigen (HBeAg) negative (-) chronic hepatitis B (CHB) is understudied. One hundred twenty-six patients with HBeAg(-)chronic hepatitis B received pegylated interferon alfa-2b > 1.5 mu g/kg/wk for 48 weeks," investigators in Greece report.

"Ninety of those subjects were randomly selected to receive concomitant treatment with lamivudine 100 mg/d. The coprimary and end points were the subjects virologic (hepatitis B virus deoxyribonucleic acid [HBV DNA] < 60 IU/mL) and biochemical (normaliazation of alanine aminotransferase levels)...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2009-05-04)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry